Follow
Susan M. Reutzel-Edens
Susan M. Reutzel-Edens
SuRE Pharma Consulting, LLC
No verified email
Title
Cited by
Cited by
Year
Facts and fictions about polymorphism
AJ Cruz-Cabeza, SM Reutzel-Edens, J Bernstein
Chemical Society Reviews 44 (23), 8619-8635, 2015
5632015
Pharmaceutical stress testing: predicting drug degradation
SW Baertschi, KM Alsante, RA Reed
CRC Press, 2016
3852016
Hydrogen bond directed cocrystallization and molecular recognition properties of acyclic imides
MC Etter, SM Reutzel
Journal of the American Chemical Society 113 (7), 2586-2598, 1991
2941991
Physical characterization of polymorphic drugs: an integrated characterization strategy
L Yu, SM Reutzel, GA Stephenson
Pharmaceutical Science & Technology Today 1 (3), 118-127, 1998
2641998
Characterization of the solid state: quantitative issues
GA Stephenson, RA Forbes, SM Reutzel-Edens
Advanced drug delivery reviews 48 (1), 67-90, 2001
2592001
Crystallization and polymorphism of conformationally flexible molecules: Problems, patterns, and strategies
L Yu, SM Reutzel-Edens, CA Mitchell
Organic Process Research & Development 4 (5), 396-402, 2000
1932000
Characterization of the “hygroscopic” properties of active pharmaceutical ingredients
AW Newman, SM Reutzel‐Edens, G Zografi
Journal of pharmaceutical sciences 97 (3), 1047-1059, 2008
1852008
Self-organization of adenine and thymine in the solid state
MC Etter, SM Reutzel, CG Choo
Journal of the American Chemical Society 115 (10), 4411-4412, 1993
1851993
Can computed crystal energy landscapes help understand pharmaceutical solids?
SL Price, DE Braun, SM Reutzel-Edens
Chemical Communications 52 (44), 7065-7077, 2016
1552016
Anhydrates and hydrates of olanzapine: crystallization, solid-state characterization, and structural relationships
SM Reutzel-Edens, JK Bush, PA Magee, GA Stephenson, SR Byrn
Crystal growth & design 3 (6), 897-907, 2003
1502003
Assessment of the amorphous “solubility” of a group of diverse drugs using new experimental and theoretical approaches
L Almeida e Sousa, SM Reutzel-Edens, GA Stephenson, LS Taylor
Molecular pharmaceutics 12 (2), 484-495, 2015
1332015
Exploring the experimental and computed crystal energy landscape of olanzapine
RM Bhardwaj, LS Price, SL Price, SM Reutzel-Edens, GJ Miller, ...
Crystal growth & design 13 (4), 1602-1617, 2013
1232013
Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine
DM Bender, J Bao, AH Dantzig, WD Diseroad, KL Law, NA Magnus, ...
Journal of medicinal chemistry 52 (22), 6958-6961, 2009
1222009
A prolific solvate former, galunisertib, under the pressure of crystal structure prediction, produces ten diverse polymorphs
RM Bhardwaj, JA McMahon, J Nyman, LS Price, S Konar, IDH Oswald, ...
Journal of the American Chemical Society 141 (35), 13887-13897, 2019
1122019
The potential of computed crystal energy landscapes to aid solid-form development
SL Price, SM Reutzel-Edens
Drug Discovery Today 21 (6), 912-923, 2016
932016
Contrasting polymorphism of related small molecule drugs correlated and guided by the computed crystal energy landscape
DE Braun, JA McMahon, LH Koztecki, SL Price, SM Reutzel-Edens
Crystal growth & design 14 (4), 2056-2072, 2014
822014
Supersaturation potential of salt, co-crystal, and amorphous forms of a model weak base
L Almeida e Sousa, SM Reutzel-Edens, GA Stephenson, LS Taylor
Crystal Growth & Design 16 (2), 737-748, 2016
792016
Coamorphous active pharmaceutical ingredient–small molecule mixtures: considerations in the choice of coformers for enhancing dissolution and oral bioavailability
A Newman, SM Reutzel-Edens, G Zografi
Journal of pharmaceutical sciences 107 (1), 5-17, 2018
772018
Polymorphism in the Pharmaceutical Industry: Solid Form and Drug Development
R Hilfiker, M Von Raumer
John Wiley & Sons, 2019
742019
Crystal structure prediction is changing from basic science to applied technology
J Nyman, SM Reutzel-Edens
Faraday Discussions 211, 459-476, 2018
652018
The system can't perform the operation now. Try again later.
Articles 1–20